date,title,source
Oct-17-18,FDA Grants Breakthrough Therapy Designation to Kadmon's KD025 for Chronic Graft-Versus-Host Disease,GlobeNewswire
Oct-18-18,"Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil  What Drives Growth in Today's Competitive Landscape",GlobeNewswire
Oct-24-18,Kadmon Announces CFO Transition and Other Updates,GlobeNewswire
Oct-25-18,Kadmon Initiates Pivotal Phase 2 Trial of KD025 in Chronic Graft-Versus-Host Disease,GlobeNewswire
Nov-01-18,Kadmon Announces Oral Presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting,GlobeNewswire
Nov-06-18,Kadmon Presents New Preclinical Data on its Immuno-Oncology Fusion Protein at SITC Annual Meeting,GlobeNewswire
Nov-07-18,Kadmon to Present at the Jefferies 2018 London Healthcare Conference,GlobeNewswire
